Lemaitre Vascular (LMAT) Research & Development (2010 - 2026)
Lemaitre Vascular (LMAT) posted quarterly Research & Development of $14.5 million for Q1 2026, up 2.13% year-over-year from $14.2 million in Q1 2025, and up 310.84% quarter-over-quarter from $3.5 million in Q4 2025.
Lemaitre Vascular (LMAT) Research & Development (2010 - 2026) Analysis & Trends
Lemaitre Vascular (LMAT) has reported Research & Development for 17 consecutive years, with $14.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 2.13% year-over-year to $14.5 million; the TTM figure through Mar 2026 stood at $35.9 million (down 15.62% YoY), while the FY2025 annual figure was $14.1 million, down 69.75% from the prior year.
- Research & Development climbed to $14.5 million in Q1 2026 per LMAT's latest filing, from $3.5 million in the prior quarter.
- Across five years, Research & Development topped out at $14.9 million in Q2 2025 and bottomed at -$13.8 million in Q4 2023.
- Historically, Research & Development has averaged $5.6 million across 5 years, with a median of $4.3 million in 2024.
- Annual changes were most pronounced in 2022 — Research & Development sank 157.1% — and 2025, when it soared 247.69%.
- Lemaitre Vascular's Research & Development stood at -$11.0 million in 2022, then fell by 25.33% to -$13.8 million in 2023, then surged by 191.36% to $12.6 million in 2024, then slumped by 72.02% to $3.5 million in 2025, then soared by 310.84% to $14.5 million in 2026.
- Business Quant data shows LMAT's Research & Development at $14.5 million in Q1 2026, $3.5 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 132.71 Bn | 127.50 Bn | 1.96 Bn | 370.60 Mn |
| 2 | Becton Dickinson | 51.57 Bn | 50.71 Bn | 2.32 Bn | 258.00 Mn |
| 3 | Alcon | 35.52 Bn | 34.17 Bn | 1.68 Bn | 663.00 Mn |
| 4 | Resmed | 33.28 Bn | 31.81 Bn | 861.22 Mn | 105.73 Mn |
| 5 | Medline | 27.86 Bn | 25.18 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 25.15 Bn | 24.71 Bn | 329.20 Mn | 19.70 Mn |
| 7 | Solventum | 15.31 Bn | 14.91 Bn | 1.29 Bn | 178.00 Mn |
| 8 | Cooper Companies | 14.86 Bn | 14.72 Bn | 735.40 Mn | 42.50 Mn |
| 9 | Baxter International | 13.63 Bn | 11.48 Bn | 1.03 Bn | 129.00 Mn |
| 10 | Lemaitre Vascular | 1.88 Bn | 1.50 Bn | 50.76 Mn | 14.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.41 Mn |
| Mar 31, 2026 | 14.52 Mn |
| Dec 31, 2025 | 3.53 Mn |
| Sep 30, 2025 | 2.97 Mn |
| Jun 30, 2025 | 14.90 Mn |
| Mar 31, 2025 | 14.21 Mn |
| Dec 31, 2024 | 12.63 Mn |
| Sep 30, 2024 | 11.44 Mn |
| Jun 30, 2024 | 4.28 Mn |
| Mar 31, 2024 | 4.09 Mn |
| Dec 31, 2023 | -13.82 Mn |
| Sep 30, 2023 | 4.22 Mn |
| Jun 30, 2023 | 10.22 Mn |
| Mar 31, 2023 | 3.88 Mn |
| Dec 31, 2022 | -11.03 Mn |
| Sep 30, 2022 | 3.46 Mn |
| Jun 30, 2022 | 8.24 Mn |
| Mar 31, 2022 | 7.85 Mn |
| Dec 31, 2021 | 19.31 Mn |
| Sep 30, 2021 | 2.85 Mn |